drugset / Trial / NCT02682082

EUS Guided Neurolysis Celiac Block w/wo Bupivacaine in Patient Being Treated Palliatively for Pancreatic Cancer

NCT02682082 ↗

RandomizedParallel-groupDouble-blindSupportive care

Summary

The goal of this project is to determine if EUS-CPN without Bupivacaine (versus EUS-CPN with Bupivacaine) can reduce pain scores and improve quality of life in patients with inoperable pancreatic cancer by reducing the morbidity due to narcotic side effects (e.g. nausea, excessive sedation, constipation).

Timeline

Start
2016-05-27
Primary completion
2019-06-14
Completion
2019-06-14

Outcome

Outcome not reported

Stopped: “Closed by CHUM REB for incomplete documentation of research activities.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 0.5 % —
Comparator Bupivacaine Other / unclassified 20 ml —